# X4 Pharmaceuticals share price today (X4 Pharmaceuticals, Inc., XFOR)

> X4 Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. XFOR · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/xfor

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $3.24 (−12.7% in a year)
- Revenue (Jun 2026): $8.8 M (+346.3% on a year ago)
- Profit (Jun 2026), incl. one-off: −$16.2 M (one-off item, see below)
- Operating margin: −186.1% (+1,143.4 points on a year ago)

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the X4 Pharmaceuticals share price today? X4 Pharmaceuticals, Inc.'s share price was $3.24 at the close on 4 November 2026. That is 14.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $5, and at that close it sat 32% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 9 weeks running. Over the last 1 year the share price moved +127% while the S&P 500 moved +18%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 4 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does X4 Pharmaceuticals pay? X4 Pharmaceuticals, Inc. pays no dividend. In the last 9 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is X4 Pharmaceuticals on? X4 Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is X4 Pharmaceuticals profitable? X4 Pharmaceuticals, Inc. posted a net loss of $16.2 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $79.2 M. That loss is 183.5% of the quarter's revenue. The same quarter a year earlier lost $25.7 M. 7 of the last 9 reported quarters were loss-making. Read this profit with care: at −$16.2 M it is bigger than the quarter's whole revenue of $8.8 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −186.1% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does X4 Pharmaceuticals make, and is it growing? X4 Pharmaceuticals, Inc. reported $8.8 M of revenue in the Jun 2026 quarter, +346.3% on the same quarter a year earlier. Over 1 years it has grown 1,273.2% a year on average. The last full year, FY25, came in at $35.1 M. The last four reported quarters add to $15.8 M. Recent pace: the last four quarters grew +137.5% on average, against 1,273.2% a year over the longer run, so this year is growing slower than its own long-run rate. ## How much of every $100 of sales does X4 Pharmaceuticals keep? X4 Pharmaceuticals, Inc.'s operating margin was −186.1% in the Jun 2026 quarter, 1,143.4 percentage points higher than the same quarter a year ago. Across 2 years it has been between −5,530.0% and −227.5%. Why the margin moved: operating margin changed +1,143.4 percentage points on the year while gross margin changed −1.9 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is X4 Pharmaceuticals' profit turning into cash? X4 Pharmaceuticals, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $85.6 M of cash, against −$79.2 M of profit. After null of spending on assets, free cash was −$85.6 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does X4 Pharmaceuticals' cash go? X4 Pharmaceuticals, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $326 K on assets over the last 1 years. Averaged over those years that is 0.9% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $326 K over the last 1 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is X4 Pharmaceuticals' P/E ratio, and how does it compare with its own history? X4 Pharmaceuticals, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values X4 Pharmaceuticals, Inc. at 9.1× its FY25 revenue of $35.1 M. The P/E comes back here once profit turns positive. ## Is the X4 Pharmaceuticals business getting better or worse? X4 Pharmaceuticals, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 5 quarters of 0 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does X4 Pharmaceuticals earn on its capital? X4 Pharmaceuticals, Inc. earned a ROE of −43% in FY25. Its return on capital used (ROIC) is left out: on sales this small it reads −6,989%, a number that says nothing useful about the business. It comes from a −225.6% net margin and 0.12× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −225.6% net margin × 0.12× asset turnover × 1.56× leverage (assets divided by equity) ≈ −42.2% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. ## Does X4 Pharmaceuticals have too much debt? X4 Pharmaceuticals, Inc. has total debt of $77.2 M against shareholder equity of $155 M as of Jun 2026, so its debt is 0.50× its equity. Year by year, that ratio went from 0.62 in FY21 to 0.41 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the X4 Pharmaceuticals shareholding pattern? 13.1% of X4 Pharmaceuticals, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 7.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is X4 Pharmaceuticals from balance-sheet trouble? For X4 Pharmaceuticals, Inc., the Z-score is −1.99. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −1.99 is inside the danger zone, so the balance sheet is a real risk. ## How does X4 Pharmaceuticals rank in its industry? There is no score against its industry: X4 Pharmaceuticals, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is X4 Pharmaceuticals compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to X4 Pharmaceuticals in size? X4 Pharmaceuticals is the 167th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: ProKidney Corp., Alector, Inc. and Benitec Biopharma Inc. Just below it: Agenus Inc., Enanta Pharmaceuticals, Inc. and Arcturus Therapeutics Holdings Inc. ### Biotechnology companies close in size

1. [ProKidney Corp.](https://www.sectoralpha.in/us/stocks/prok) $339 million
2. [Alector, Inc.](https://www.sectoralpha.in/us/stocks/alec) $338 million
3. [Benitec Biopharma Inc.](https://www.sectoralpha.in/us/stocks/bntc) $324 million
4. X4 Pharmaceuticals, Inc. $321 million
5. [Agenus Inc.](https://www.sectoralpha.in/us/stocks/agen) $314 million
6. [Enanta Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/enta) $310 million
7. [Arcturus Therapeutics Holdings Inc.](https://www.sectoralpha.in/us/stocks/arct) $309 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Platinum Analytics Cayman Limited](https://www.sectoralpha.in/us/stocks/plts) $316 million · Software - Application
2. [FTAI Infrastructure Inc.](https://www.sectoralpha.in/us/stocks/fip) $316 million · Conglomerates
3. X4 Pharmaceuticals, Inc. $314 million
4. [American Realty Investors, Inc.](https://www.sectoralpha.in/us/stocks/arl) $314 million · Real Estate Services
5. [Presidio Production Company](https://www.sectoralpha.in/us/stocks/ftw) $314 million · Oil & Gas Exploration & Production

## What else do people ask about X4 Pharmaceuticals? ### What were X4 Pharmaceuticals's latest quarterly results? X4 Pharmaceuticals, Inc. reported revenue of $8.8 M and a net loss of $16.2 M for the Jun 2026 quarter. Earnings per share were −$0.13. The operating margin was −186.1%, 1,143.4 percentage points higher than a year earlier (as of 4 November 2026). ### What is X4 Pharmaceuticals's market cap? X4 Pharmaceuticals, Inc.'s market capitalisation is $321 M at a stock price of $3.24. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is X4 Pharmaceuticals performing? X4 Pharmaceuticals, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 9 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will X4 Pharmaceuticals's stock price go up? This page does not forecast X4 Pharmaceuticals, Inc.'s stock price. What it shows instead: the stock price is $3.24. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Does X4 Pharmaceuticals have too much debt? X4 Pharmaceuticals, Inc. has a moderate amount of debt: its debt is 0.56× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 4 November 2026). ### Where is X4 Pharmaceuticals in its business cycle? X4 Pharmaceuticals, Inc.'s FY25 operating margin was −227.5%, against a 2-year range of −5,530.0% to −227.5%: the middle of its own range, neither a peak nor a low. The latest quarter was −186.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the X4 Pharmaceuticals story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is X4 Pharmaceuticals a stock worth studying right now? What the numbers show: X4 Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.